Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RaparoBell vs MMF in ABO-Incompatible Kidney Transplant
NCT04700709Phase 4Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of RaparoBell in kidney transplant rejection, sponsored by Chong Kun Dang Holdings. Status: unknown.
02
Drugs
RaparoBell
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04700709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04700709.